药物遗传学对注意缺陷多动障碍儿童盐酸哌甲酯治疗的影响

doi:10.11852/zgetbjzz2023-0489

中国儿童保健杂志 ›› 2024, Vol. 32 ›› Issue (3): 296-300.DOI: 10.11852/zgetbjzz2023-0489

药物遗传学对注意缺陷多动障碍儿童盐酸哌甲酯治疗的影响

任苗苗, 陈立

重庆医科大学附属儿童医院儿童保健科(健康管理部) / 国家儿童健康与疾病临床医学研究中心/儿童发育疾病研究教育部重点实验室/ 儿童发育重大疾病国家国际科技合作基地/儿童营养与健康重庆市重点实验室,重庆 400014

收稿日期:2023-05-17 修回日期:2023-09-28 发布日期:2024-03-04 出版日期:2024-03-10
通讯作者: 陈立,E-mail:chenli@cqmu.edu.cn
作者简介:任苗苗(1996-),住院医师,在读硕士研究生,主要研究方向为儿童发育障碍性疾病。
基金资助:
重庆市科卫联合医学科研项目重点项目(2018ZDXM012)

Pharmacogenetic impact on the methylphenidate-hydrocloride treatment in children with attention-deficit hyperactivity disorder

REN Miaomiao, CHEN Li

Child Healthcare Department (Health Management Department), Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Child Nutrition and Health, Chongqing 400014

Received:2023-05-17 Revised:2023-09-28 Online:2024-03-10 Published:2024-03-04
Contact: CHEN Li,E-mail:chenli@cqmu.edu.cn

摘要/Abstract

摘要： 注意缺陷多动障碍(ADHD)是儿童期最常见的慢性神经发育障碍之一,以与发育水平不匹配的注意力不集中、多动冲动为主要表现,可能导致多种功能损害,给个人、家庭、社会带来沉重负担。盐酸哌甲酯(MPH)是一种ADHD一线治疗药物,临床应用广泛,但部分患者对药物治疗无反应、出现不良反应等原因过早终止治疗。在治疗中引入药物遗传学的概念可能为 ADHD的个体化干预开辟新的途径。本文旨在综述药物遗传学对ADHD儿童MPH治疗的影响,为临床药物治疗及管理提供参考。

关键词: 注意缺陷多动障碍, 药物遗传学, 盐酸哌甲酯, 药代动力学, 药效动力学

Abstract: Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic neurodevelopmental disorders in childhood.It is mainly manifested as inattention, hyperactivity, and impulsivity that are inconsistent with the development level, which may lead to multiple functional impairments and place heavy burdens on individuals, families, and society.Methylphenidate hydrochloride (MPH) is a first-line treatment drug for ADHD, which is widely used in clinical practice.However, some patients have no response to drug treatment and adverse reactions often cause premature termination of treatment.Introducing the concept of pharmacogenetics into MPH treatment may open new avenues for individualized interventions of ADHD.This paper aims to review the impact of pharmacogenetics on MPH treatment in children with ADHD and to provide references for clinical drug treatment and management.

Key words: attention-deficit hyperactivity disorder, pharmacogenetics, methylphenidate-hydrocloride, pharmacokinetics, pharmacodynamics

中图分类号:

R749.94

任苗苗, 陈立. 药物遗传学对注意缺陷多动障碍儿童盐酸哌甲酯治疗的影响[J]. 中国儿童保健杂志, 2024, 32(3): 296-300.

REN Miaomiao, CHEN Li. Pharmacogenetic impact on the methylphenidate-hydrocloride treatment in children with attention-deficit hyperactivity disorder[J]. Chinese Journal of Child Health Care, 2024, 32(3): 296-300.

参考文献

[1] 中华医学会儿科学分会发育行为学组.注意缺陷多动障碍早期识别、规范诊断和治疗的儿科专家共识[J].中华儿科杂志, 2020, 58(3):188-193.
The Subspecialty Group of Developmental and Behavioral Pediatrics, the Society of Pediatrics, Chinese Medical Association.Consensus on pediatric clinical practice of early identification, standardized diagnosis and treatment of attention deficit hyperactivity disorder[J].Chin J Pediatr, 2020, 58(3):188-193.(in Chinese)
[2] Posner J, Polanczyk G V, Sonuga-Barke E.Attention-deficit hyperactivity disorder[J].Lancet, 2020, 395(10222):450-462.
[3] Wang T, Liu K, Li Z, et al.Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China: A systematic review and meta-analysis[J].BMC Psychiatry, 2017, 17(1):32.
[4] Thomas R, Sanders S, Doust J, et al.Prevalence of attention-deficit/hyperactivity disorder: A systematic review and Meta-analysis[J].Pediatrics, 2015, 135(4):e994-e1001.
[5] Raman SR, Man KKC, Bahmanyar S, et al.Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases[J].Lancet Psychiatry, 2018, 5(10):824-835.
[6] Johnston BA, Coghill D, Matthews K, et al.Predicting methylphenidate response in attention deficit hyperactivity disorder: A preliminary study[J].J Psychopharmacol, 2015, 29(1):24-30.
[7] Faraone SV.Molecular genetics of attention deficit hyperactivity disorder[J].Psychiatr Clin North Am, 2010, 33(1):159-180.
[8] Wenthur CJ.Classics in chemical neuroscience: Methylphenidate[J].ACS Chem Neurosci, 2016, 7(8):1030-1040.
[9] Steingard R, Taskiran S, Connor DF, et al.New formulations of stimulants: An update for clinicians[J].J Child Adolesc Psychopharmacol, 2019, 29(5):324-339.
[10] Markowitz JS, Melchert PW.The pharmacokinetics and pharmacogenomics of psychostimulants[J].Child Adolesc Psychiatr Clin N Am, 2022, 31(3):393-416.
[11] Zhu HJ, Patrick KS, Yuan HJ, et al.Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in Man: Clinical significance and molecular basis[J].Am J Hum Genet, 2008, 82(6):1241-1248.
[12] Merali Z, Ross S, Paré G.The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect[J].Drug Metabol Drug Interact, 2014, 29(3).
[13] Stage C, Jürgens G, Guski L S, et al.The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects: Impact of CES1 genotype on methylphenidate pharmacokinetics[J].Br J Clin Pharmacol, 2017, 83(7):1506-1514.
[14] Stage C, Dalhoff K, Rasmussen HB, et al.The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios[J].Basic Clin Pharmacol Toxicol, 2019, 125(1):54-61.
[15] Lyauk Y, Stage C, Bergmann T, et al.Population pharmacokinetics of methylphenidate in healthy adults emphasizing novel and known effects of several carboxylesterase 1 (CES1) Variants[J].Clin Transl Sci, 2016, 9(6):337-345.
[16] Newcorn J.Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD[EB/OL].(2018-12-20)[2023-01-10].https://clinicaltrials.gov/.
[17] Nemoda Z, Angyal N, Tarnok Z, et al.Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD[J].Neuropharmacology, 2009, 57(7-8):731-733.
[18] Stevens T, Sangkuhl K, Brown J T, et al.PharmGKB summary: Methylphenidate pathway, pharmacokinetics/pharmacodynamics[J].Pharmacogenet Genomics, 2019, 29(6):136-154.
[19] Brown JT, Beery N, Taran A, et al.Associations between CES1 variants and dosing and adverse effects in children taking methylphenidate[J].Front Pediatr, 2023, 10: 958622.
[20] Zhu HJ, Appel DI, Peterson YK, et al.Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: Potential sources of metabolic drug interactions[J].Toxicology, 2010, 270(2-3):59-65.
[21] Faraone SV, Larsson H.Genetics of attention deficit hyperactivity disorder[J].Mol Psychiatry, 2019, 24(4):562-575.
[22] Akutagava-Martins GC, Rohde LA, Hutz MH.Genetics of attention-deficit/hyperactivity disorder: An update[J].Expert Rev Neurother, 2016, 16(2):145-156.
[23] Quintero J, Gutiérrez-Casares JR, Álamo C.Molecular characterisation of the mechanism of action of stimulant drugs lisdexamfetamine and methylphenidate on ADHD neurobiology: A review[J].Neurol Ther, 2022, 11(4):1489-1517.
[24] Cortese S.Pharmacologic treatment of attention deficit-hyperactivity disorder[J].N Engl J Med, 2020, 383(11):1050-1056.
[25] Faraone SV.The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities[J].Neurosci Biobehav Rev, 2018, 87: 255-270.
[26] Grünblatt E, Werling AM, Roth A, et al.Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder[J].J Neural Transm (Vienna), 2019, 126(4):517-529.
[27] Soleimani R, Salehi Z, Soltanipour S, et al.SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis[J].Am J Med Genet B Neuropsychiatr Genet, 2018, 177(3):287-300.
[28] Kambeitz J, Romanos M, Ettinger U.Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD[J].Pharmacogenomics J, 2014, 14(1):77-84.
[29] Hong SB, Kim JW, Cho SC, et al.Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in Korean children with attention-deficit/hyperactivity disorder: Is there an interaction?[J].J Child Adolesc Psychopharmacol, 2012, 22(5):343-352.
[30] Pappa I, Mileva-Seitz VR, Bakermans-Kranenburg MJ, et al.The magnificent seven: A quantitative review of dopamine receptor d4 and its association with child behavior[J].Neurosci Biobehav Rev, 2015, 57: 175-186.
[31] Myer NM, Boland J R, Faraone SV.Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD[J].Mol Psychiatry, 2018, 23(9):1929-1936.
[32] Bonvicini C, Cortese S, Maj C, et al.DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder[J].Transl Psychiatry, 2020, 10(1):70.
[33] Naumova D, Grizenko N, Sengupta SM, et al.DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation of treatment response to methylphenidate[J].World J Biol Psychiatry, 2019, 20(6):486-495.
[34] Lario S, Calls J, Cases A, et al.MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene[J].Clin Genet, 1997, 51(2):129-130.
[35] Froehlich TE, Epstein JN, Nick TG, et al.Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder[J].J Am Acad Child Adolesc Psychiatry, 2011, 50(11):1129-1139.e2.
[36] Yuan D, Zhang M, Huang Y, et al.Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis[J].Medicine (Baltimore), 2021, 100(46):e27858.
[37] Gomez-Sanchez CI, Carballo JJ, Riveiro-Alvarez R, et al.Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: Long-term effects[J].Sci Rep, 2017, 7(1):10391.
[38] Kim BN, Cummins TDR, Kim JW, et al.Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children[J].Int J Neuropsychopharmacol, 2011, 14(10):1399-1410.
[39] Park S, Kim JW, Kim BN, et al.No significant association between the alpha-2a-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder[J].Pharmacopsychiatry, 2013, 46(5):169-174.
[40] Sun H, Yuan F, Shen X, et al.Role of COMT in ADHD: A systematic meta-analysis[J].Mol Neurobiol, 2014, 49(1):251-261.
[41] 陈敏, 陈芸, 汤宜朗, 等.单胺氧化酶A基因单体型预测注意缺陷多动障碍哌甲酯治疗的反应[J].中国心理卫生杂志, 2014, 28(10):748-753.
Chen M, Chen Y, Tang YL, et al.Association of better methylphenidate response with a haplotype of monoamine oxidase A gene in the treatment of attention-deficit/hyperactivity disorder[J].Chin Ment Health J, 2014, 28(10):748-753.(in Chinese)
[42] Angyal N, Horvath EZ, Tarnok Z, et al.Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients[J].Prog Neuropsychopharmacol Biol Psychiatry, 2018, 84: 122-128.
[43] 丁凯景, 丁雨钦, 刘艳, 等.GRIN2A、GRIN2B基因多态性与哌甲酯治疗注意缺陷多动障碍疗效的关系研究[J].浙江医学, 2022, 44(19):2064-2069.
Ding KJ, Ding YQ, Liu Y, et al.Association of GRIN2A, GRIN2B gene polymorphisms and the efficacy of methylphenidate in treatment of attention deficit hyperactivity disorder[J].Zhejiang Med, 2022, 44(19):2064-2069.(in Chinese)

药物遗传学对注意缺陷多动障碍儿童盐酸哌甲酯治疗的影响

Pharmacogenetic impact on the methylphenidate-hydrocloride treatment in children with attention-deficit hyperactivity disorder

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	毛广惠, 王丹, 李丽丽, 季忆婷, 王琪玉, 冯晨霞, 赵晓燕, 何璐, 蔡世忠, 陈艳. 学龄期注意缺陷多动障碍儿童的人体成分分析[J]. 中国儿童保健杂志, 2024, 32(9): 1029-1033.
[2]	邓梁琼, 梁媛媛, 岑诗, 胡敏, 李红辉, 曾烜, 廖林燕. 新森林教养方案对注意缺陷多动障碍儿童干预疗效的研究[J]. 中国儿童保健杂志, 2024, 32(8): 856-861.
[3]	章依文. 注意缺陷多动障碍共病智力障碍的诊治挑战[J]. 中国儿童保健杂志, 2024, 32(6): 581-585.
[4]	冯廷勇, 王雪珂. 注意缺陷多动障碍儿童多模态评估的现状与建议[J]. 中国儿童保健杂志, 2024, 32(6): 586-590.
[5]	刘子奇, 刘思奇, 陶梦娇, 任永颖, 李冠男, 孙静, 王昕, 张建昭, 杨健. 不同注意力、控制力水平注意缺陷多动障碍儿童认知功能特点[J]. 中国儿童保健杂志, 2024, 32(6): 591-596.
[6]	张琳琳, 吴赵敏, 王鹏, 操小兰, 刘娟, 王玉凤, 杨斌让. 高焦虑水平注意缺陷多动障碍儿童社会功能损害特征[J]. 中国儿童保健杂志, 2024, 32(6): 597-601.
[7]	郭春燕, 宋丽, 王亚哲, 于茹梦, 张定方, 殷梦华. 注意缺陷多动障碍共患学习障碍儿童的执行功能研究[J]. 中国儿童保健杂志, 2024, 32(6): 602-607.
[8]	卢鋆锋, 李甦. 注意缺陷多动障碍儿童语用性语言障碍研究进展[J]. 中国儿童保健杂志, 2024, 32(6): 643-647.
[9]	胡旖婷, 江克文. 注意缺陷多动障碍儿童执行功能性别差异及机制研究进展[J]. 中国儿童保健杂志, 2024, 32(6): 648-652.
[10]	吴泳华, 于敬龙, 周康宁, 王俊宏. 基于CiteSpace的近十年国内外注意缺陷多动障碍认知功能的可视化分析[J]. 中国儿童保健杂志, 2024, 32(6): 661-667.
[11]	李梦滔, 代梦琴, 罗尧竞, 赵小燕. 学龄期注意缺陷多动障碍儿童社交焦虑现状及影响因素[J]. 中国儿童保健杂志, 2024, 32(3): 344-348.
[12]	陆彦婷, 陈亮亮, 刘秀梅. 先兆冲动在共患注意缺陷多动障碍与抽动障碍儿童抽动严重程度关联中的中介作用[J]. 中国儿童保健杂志, 2024, 32(10): 1050-1054.
[13]	张沥文, 秦星, 李娟, 宋紫霞, 吴玮玮. 脑电生物反馈联合盐酸哌甲酯治疗儿童注意缺陷多动障碍的疗效及对脑血流和血清皮质醇水平的影响[J]. 中国儿童保健杂志, 2024, 32(10): 1135-1139.
[14]	董超, 张琳琳, 钟蕴瑜, 刘云, 刘娟, 王鹏, 王玉凤, 杨斌让, 吴赵敏, 李颖. 利用剑桥自动化神经心理测验包探查注意缺陷多动障碍儿童多维度执行功能缺陷[J]. 中国儿童保健杂志, 2024, 32(10): 1149-1154.
[15]	郑宇霞, 王惠萍, 王左华, 杨艳飞, 张霞. 儿童注意缺陷多动障碍影响因素及骨密度与体格生长的相关性分析[J]. 中国儿童保健杂志, 2024, 32(1): 98-102.